Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury?

Radboud University Medical Center

Status and phase

Completed

Phase 4

Conditions

Ischemia-Reperfusion Injury

Cardiovascular Disease

Treatments

Drug: caffeine

Drug: Dipyridamole

Study type

Interventional

Funder types

Other

Identifiers

NCT00430170

dipy001

Details and patient eligibility

About

The purpose of this project is to explore the interaction between caffeine and dipyridamole on ischemia-reperfusion injury in the forearm.

Full description

Dipyridamole has been proven to reduce targeting of Annexin A5 in responses to ischemic exercise, indicating protection against ischemia-reperfusion injury in humans (pharmacological preconditioning). Dipyridamole increases the endogenous adenosine level by inhibition of the nucleoside transporter (ENT-1). Activation of the adenosine receptor protects against ischemia-reperfusion injury. We hypothesize that endogenous adenosine mediates the protective effect of dipyridamole against ischemia-reperfusion injury. Therefore the adenosine receptor antagonist caffeine will reduce the benefit of dipyridamole on forearm ischemia-reperfusion injury.

Enrollment

20 patients

Sex

Male

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Male
Age between 18-50yr.

Exclusion criteria

cardiovascular disease
hypertension (systole > 140 mmHg, diastole > 90 mmHg)
hypercholesterolemia (random total cholesterol > 6.5 mmol/l)
diabetes mellitus (fasting glucose > 7.0 mmol/L or random glucose > 11.0 mmol/L)
asthma (recurrent episodes of dyspnea and wheezing, or usage of prescribed inhalation medication: i.e. corticosteroids or B2-agonists)
participation in any clinical trial during the last 60 days prior to this study.
administration of two doses of Annexin A5 (0,1mg; 450MBq) during the last 5 years prior to this study.